Serum osteocalcin and insulin-like growth factor I levels in children with congenital adrenal hyperplasia

Gábor Hargitai, É Hosszú, Z. Halász, J. Sólyom

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Patients with the virilizing forms of congenital adrenal hyperplasia (CAH) need a life-long glucocorticoid replacement therapy and also an additional mineralocorticoid replacement in cases with the salt-wasting form of the disease. Glucocorticoids are reported to decrease the serum osteocalcin levels and to inhibit the effects of insulin-like growth factor I (IGF-I). To collect data on the age related patterns of osteocalcin and IGF-I production in patients with CAH, measurements of these compounds have been carried out in a considerably large sample of treated CAH patients and control subjects in childhood and adolescence. Data of 62 patients between 0.3-19 years of age were compared to the data of 188 control children. Osteocalcin and IGF-I were determined by radioimmunoassay. A lower than normal level of serum osteocalcin was found in both male and female patients at chronological ages above 11.6 and 9.6 years, respectively. Furthermore, no pubertal osteocalcin peak could be seen when data were evaluated according to the bone age. Serum IGF-I levels were higher in male CAH patients at the chronological age of 0.3-15.5 years and in female patients at the chronological age of 4.6-9.5 years. In pubertal years serum IGF-I concentrations were lower in CAH patients when data were evaluated according to the bone age. We conclude that serum osteocalcin is decreased during and after puberty in CAH patients on replacement doses of glucocorticoids. Normal to elevated serum levels of IGF-I in treated CAH cases suggest that the shorter final height of these patients may not be due to the decreased activity in the growth hormone-IGF-I axis, but rather to the advanced bone maturation and the premature epiphyseal fusion. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish
Pages (from-to)131-139
Number of pages9
JournalHormone Research
Volume52
Issue number3
Publication statusPublished - 1999

Fingerprint

Congenital Adrenal Hyperplasia
Osteocalcin
Insulin-Like Growth Factor I
Serum
Glucocorticoids
Bone and Bones
Wasting Syndrome
Mineralocorticoids
Puberty
Growth Hormone
Radioimmunoassay
Salts

Keywords

  • Congenital adrenal hyperplasia
  • Serum insulin-like growth factor I
  • Serum osteocalcin

ASJC Scopus subject areas

  • Endocrinology

Cite this

Serum osteocalcin and insulin-like growth factor I levels in children with congenital adrenal hyperplasia. / Hargitai, Gábor; Hosszú, É; Halász, Z.; Sólyom, J.

In: Hormone Research, Vol. 52, No. 3, 1999, p. 131-139.

Research output: Contribution to journalArticle

Hargitai, Gábor ; Hosszú, É ; Halász, Z. ; Sólyom, J. / Serum osteocalcin and insulin-like growth factor I levels in children with congenital adrenal hyperplasia. In: Hormone Research. 1999 ; Vol. 52, No. 3. pp. 131-139.
@article{3f44d3cf6b4d443fb1d05e4d4db2ffee,
title = "Serum osteocalcin and insulin-like growth factor I levels in children with congenital adrenal hyperplasia",
abstract = "Patients with the virilizing forms of congenital adrenal hyperplasia (CAH) need a life-long glucocorticoid replacement therapy and also an additional mineralocorticoid replacement in cases with the salt-wasting form of the disease. Glucocorticoids are reported to decrease the serum osteocalcin levels and to inhibit the effects of insulin-like growth factor I (IGF-I). To collect data on the age related patterns of osteocalcin and IGF-I production in patients with CAH, measurements of these compounds have been carried out in a considerably large sample of treated CAH patients and control subjects in childhood and adolescence. Data of 62 patients between 0.3-19 years of age were compared to the data of 188 control children. Osteocalcin and IGF-I were determined by radioimmunoassay. A lower than normal level of serum osteocalcin was found in both male and female patients at chronological ages above 11.6 and 9.6 years, respectively. Furthermore, no pubertal osteocalcin peak could be seen when data were evaluated according to the bone age. Serum IGF-I levels were higher in male CAH patients at the chronological age of 0.3-15.5 years and in female patients at the chronological age of 4.6-9.5 years. In pubertal years serum IGF-I concentrations were lower in CAH patients when data were evaluated according to the bone age. We conclude that serum osteocalcin is decreased during and after puberty in CAH patients on replacement doses of glucocorticoids. Normal to elevated serum levels of IGF-I in treated CAH cases suggest that the shorter final height of these patients may not be due to the decreased activity in the growth hormone-IGF-I axis, but rather to the advanced bone maturation and the premature epiphyseal fusion. Copyright (C) 2000 S. Karger AG, Basel.",
keywords = "Congenital adrenal hyperplasia, Serum insulin-like growth factor I, Serum osteocalcin",
author = "G{\'a}bor Hargitai and {\'E} Hossz{\'u} and Z. Hal{\'a}sz and J. S{\'o}lyom",
year = "1999",
language = "English",
volume = "52",
pages = "131--139",
journal = "Hormone Research in Paediatrics",
issn = "1663-2818",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Serum osteocalcin and insulin-like growth factor I levels in children with congenital adrenal hyperplasia

AU - Hargitai, Gábor

AU - Hosszú, É

AU - Halász, Z.

AU - Sólyom, J.

PY - 1999

Y1 - 1999

N2 - Patients with the virilizing forms of congenital adrenal hyperplasia (CAH) need a life-long glucocorticoid replacement therapy and also an additional mineralocorticoid replacement in cases with the salt-wasting form of the disease. Glucocorticoids are reported to decrease the serum osteocalcin levels and to inhibit the effects of insulin-like growth factor I (IGF-I). To collect data on the age related patterns of osteocalcin and IGF-I production in patients with CAH, measurements of these compounds have been carried out in a considerably large sample of treated CAH patients and control subjects in childhood and adolescence. Data of 62 patients between 0.3-19 years of age were compared to the data of 188 control children. Osteocalcin and IGF-I were determined by radioimmunoassay. A lower than normal level of serum osteocalcin was found in both male and female patients at chronological ages above 11.6 and 9.6 years, respectively. Furthermore, no pubertal osteocalcin peak could be seen when data were evaluated according to the bone age. Serum IGF-I levels were higher in male CAH patients at the chronological age of 0.3-15.5 years and in female patients at the chronological age of 4.6-9.5 years. In pubertal years serum IGF-I concentrations were lower in CAH patients when data were evaluated according to the bone age. We conclude that serum osteocalcin is decreased during and after puberty in CAH patients on replacement doses of glucocorticoids. Normal to elevated serum levels of IGF-I in treated CAH cases suggest that the shorter final height of these patients may not be due to the decreased activity in the growth hormone-IGF-I axis, but rather to the advanced bone maturation and the premature epiphyseal fusion. Copyright (C) 2000 S. Karger AG, Basel.

AB - Patients with the virilizing forms of congenital adrenal hyperplasia (CAH) need a life-long glucocorticoid replacement therapy and also an additional mineralocorticoid replacement in cases with the salt-wasting form of the disease. Glucocorticoids are reported to decrease the serum osteocalcin levels and to inhibit the effects of insulin-like growth factor I (IGF-I). To collect data on the age related patterns of osteocalcin and IGF-I production in patients with CAH, measurements of these compounds have been carried out in a considerably large sample of treated CAH patients and control subjects in childhood and adolescence. Data of 62 patients between 0.3-19 years of age were compared to the data of 188 control children. Osteocalcin and IGF-I were determined by radioimmunoassay. A lower than normal level of serum osteocalcin was found in both male and female patients at chronological ages above 11.6 and 9.6 years, respectively. Furthermore, no pubertal osteocalcin peak could be seen when data were evaluated according to the bone age. Serum IGF-I levels were higher in male CAH patients at the chronological age of 0.3-15.5 years and in female patients at the chronological age of 4.6-9.5 years. In pubertal years serum IGF-I concentrations were lower in CAH patients when data were evaluated according to the bone age. We conclude that serum osteocalcin is decreased during and after puberty in CAH patients on replacement doses of glucocorticoids. Normal to elevated serum levels of IGF-I in treated CAH cases suggest that the shorter final height of these patients may not be due to the decreased activity in the growth hormone-IGF-I axis, but rather to the advanced bone maturation and the premature epiphyseal fusion. Copyright (C) 2000 S. Karger AG, Basel.

KW - Congenital adrenal hyperplasia

KW - Serum insulin-like growth factor I

KW - Serum osteocalcin

UR - http://www.scopus.com/inward/record.url?scp=0033507348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033507348&partnerID=8YFLogxK

M3 - Article

C2 - 10725777

AN - SCOPUS:0033507348

VL - 52

SP - 131

EP - 139

JO - Hormone Research in Paediatrics

JF - Hormone Research in Paediatrics

SN - 1663-2818

IS - 3

ER -